RecruitingNCT05433935

Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas

A Prospective, Open Large Cohort Study of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas


Sponsor

Zhejiang University

Enrollment

5,000 participants

Start Date

Jul 1, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

This is a prospective, open large cohort study to explore biomarkers for detecting early carcinogenesis of IPMN.


Eligibility

Min Age: 0 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating biological markers in patients with a type of pancreatic cyst called Intraductal Papillary Mucinous Neoplasm (IPMN). Some IPMNs can develop into pancreatic cancer over time, and this study aims to find early warning signals in the blood or tissue that might predict which ones are dangerous. **You may be eligible if:** - You have been clinically diagnosed with IPMN (a type of pancreatic cyst) - You do not have another active cancer - You are willing to sign an informed consent form **You may NOT be eligible if:** - You have a mental disorder that affects your ability to cooperate - You have a serious blood disorder or are taking medications that affect blood composition Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERObservation

This is an observational study.


Locations(1)

the First Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05433935


Related Trials